Summary:

• There is an increased risk of thrombotic complications, including cerebral infarction, upon abrupt anagrelide discontinuation.
• Abrupt treatment discontinuation should be avoided due to the risk of sudden increase in platelet counts and potentially fatal thrombotic complications, such as cerebral infarction.
• In the event of dosage interruption or treatment withdrawal, monitor platelet counts frequently (refer to SmPC Section 4.4).
• Advise patients how to recognize early signs and symptoms suggestive of thrombotic complications, such as cerebral infarction, and if symptoms occur to seek medical assistance.